Reaction equation
COc1nc(N)ccc1-n1cnc(C)c1.Cc1cnc(C2CN(C)Cc3ccc(Cl)nc3O2)s1>CC(=O)O.CC(=O)O.COCCOC.O=C([O-])[O-].[Cs+].[Cs+].[Pd].c1ccc(-c2ccccc2P(C2CCCCC2)C2CCCCC2)cc1>COc1nc(Nc2ccc3c(n2)OC(c2ncc(C)s2)CN(C)C3)ccc1-n1cnc(C)c1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 4
Conditions
- Temperature
- 100 °C
Procedure
8-chloro-4-methyl-2-(5-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine (140 mg, 0.47 mmol), 6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-amine (106 mg, 0.52 mmol), 2-(DICYCLOHEXYLPHOSPHINO)BIPHENYL (16.59 mg, 0.05 mmol), PALLADIUM(II) ACETATE (10.63 mg, 0.05 mmol) and Cs2CO3 (308 mg, 0.95 mmol) were weighed into a microwave vial, the vial was capped and DME (4 mL) was added. The vial was flushed with argon and heated to 100°C in a microwave reactor for 1 h. The reaction mixture was diluted with dichloromethane and filtered and the solvents were evaporated. The residue was purified by column chromatography on Silica using gradient elution with methanol in dichloromethane (0-6 %) to give N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methyl-2-(5-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine (162 mg, 73.8 %).
Sources & evidence
- ORD record
- ord-771383a2857c4cf6924928bdcc9bb648
- Source dataset
- 750 AstraZeneca ELN dataset
- Original link
- View source
Linked notes
Loading…